DK0812206T3 - Fremgangsmåde til stimulering af en immunrespons - Google Patents

Fremgangsmåde til stimulering af en immunrespons

Info

Publication number
DK0812206T3
DK0812206T3 DK96909555T DK96909555T DK0812206T3 DK 0812206 T3 DK0812206 T3 DK 0812206T3 DK 96909555 T DK96909555 T DK 96909555T DK 96909555 T DK96909555 T DK 96909555T DK 0812206 T3 DK0812206 T3 DK 0812206T3
Authority
DK
Denmark
Prior art keywords
immune response
stimulating
individuals
pathogenic
ligand
Prior art date
Application number
DK96909555T
Other languages
English (en)
Inventor
Charles R Maliszewski
Mark Alderson
Kim A Campbell
Mary K Kennedy
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0812206T3 publication Critical patent/DK0812206T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK96909555T 1995-03-01 1996-02-29 Fremgangsmåde til stimulering af en immunrespons DK0812206T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01
PCT/US1996/002839 WO1996026735A1 (en) 1995-03-01 1996-02-29 Method for stimulating an immune response

Publications (1)

Publication Number Publication Date
DK0812206T3 true DK0812206T3 (da) 2002-09-09

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96909555T DK0812206T3 (da) 1995-03-01 1996-02-29 Fremgangsmåde til stimulering af en immunrespons

Country Status (15)

Country Link
EP (1) EP0812206B1 (da)
JP (1) JP3657271B2 (da)
KR (1) KR19980702490A (da)
AT (1) ATE220331T1 (da)
AU (1) AU699291B2 (da)
CA (1) CA2213798C (da)
DE (1) DE69622259T2 (da)
DK (1) DK0812206T3 (da)
ES (1) ES2179187T3 (da)
FI (1) FI973484L (da)
MX (1) MX9706588A (da)
NO (1) NO973875L (da)
NZ (1) NZ305083A (da)
PT (1) PT812206E (da)
WO (1) WO1996026735A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
JP2001526241A (ja) * 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
ES2330017T3 (es) * 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
NO2525817T3 (da) 2010-01-21 2018-01-06
BR112012031211A2 (pt) 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
MX2021012471A (es) 2019-04-11 2022-01-04 Univ Arkansas Aptameros de adn especificos de cd40 como adyuvantes de vacunas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283541B1 (ko) * 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
KR960704576A (ko) * 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 CD40에 대한 항체(Antibodies to CD40)

Also Published As

Publication number Publication date
NO973875L (no) 1997-10-31
NZ305083A (en) 1999-06-29
JP3657271B2 (ja) 2005-06-08
CA2213798C (en) 2001-02-06
DE69622259T2 (de) 2003-03-27
AU5301196A (en) 1996-09-18
KR19980702490A (ko) 1998-07-15
DE69622259D1 (de) 2002-08-14
EP0812206B1 (en) 2002-07-10
CA2213798A1 (en) 1996-09-06
ES2179187T3 (es) 2003-01-16
ATE220331T1 (de) 2002-07-15
MX9706588A (es) 1997-11-29
FI973484A7 (fi) 1997-10-24
FI973484L (fi) 1997-10-24
PT812206E (pt) 2002-11-29
NO973875D0 (no) 1997-08-22
WO1996026735A1 (en) 1996-09-06
JPH11506418A (ja) 1999-06-08
AU699291B2 (en) 1998-11-26
FI973484A0 (fi) 1997-08-25
EP0812206A1 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
DK0724456T3 (da) CD40-Antistoffer
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
NO933126L (no) Löselige ligander for CD40
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
ATE213507T1 (de) Methode zur bindung von material an das beta- amyloid-peptid
EP1715045A3 (en) Recombinant antibodies for human therapy
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
EP0914155A4 (en) PROSTATE SPECIFIC MEMBRANE ANTIGEN MONOCLONAL ANTIBODIES
CA2429027A1 (en) Antibodies against human receptor h4-1bb
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
NO971059L (no) Modifiserte human-C3-proteiner
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
EA199700196A1 (ru) Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом
ATE309371T1 (de) Protein mit dnase-aktivität
DE69118702D1 (de) Neue verwendung eines monoklonalen antikörpers